PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2125420
PUBLISHER: Mordor Intelligence | PRODUCT CODE: 2125420
According to Mordor Intelligence, the Italy ultrasound devices market size is expected to grow from USD 278.58 million in 2025 to USD 289.38 million in 2026 and is forecast to reach USD 356.48 million by 2031 at 4.26% CAGR over 2026-2031.

This report is Segmented by Application (Anesthesiology, Cardiology, Gynecology/Obstetrics, Musculoskeletal, Radiology, and More), Technology (2D Ultrasound Imaging, 3D & 4D Ultrasound Imaging, and More), Portability (Stationary Systems, and More), End User (Hospitals, Diagnostic Centers, and More). The Market Forecasts are Provided in Terms of Value (USD) and Volume (Units).
Italy's population aged >= 65 continues to expand, elevating demand for ultrasound in cardiology, musculoskeletal, and vascular care. Hospitals prefer ultrasound over ionizing imaging for frail patients because it is bedside-ready, cost-efficient, and radiation-free. Geriatric wards increasingly rely on cart-based consoles for pleural-effusion checks and bladder scanning, while adding handheld probes for ward rounds. Stable reimbursement under the SSN assures high utilization, sustaining the replacement cycle for legacy fleets and reinforcing the trajectory of the Italy ultrasound devices market.
3D and 4D ultrasound dominate value, as obstetrics departments follow the protocols of the Societa Italiana di Ecografia Ostetrica e Ginecologica, which mandate detailed anatomy scans. AI modules such as GE HealthCare's SonoLyst trim examination time by 65%, while cardiac departments validate handheld AI tools that approximate MRI-derived ejection fraction. Hospitals justify the premium by quantifying throughput gains and consistent measurements, prompting vendors to monetize software upgrades across installed bases.
Premium 3D/4D consoles list at EUR 100,000-150,000, with annual service at 8-12% of purchase price, challenging hospitals in Calabria, Campania, and Sicily, where per-capita health spending trails the national mean. PNRR tenders favor mid-tier platforms costing EUR 82,000, but leasing and pay-per-use models remain scarce. Cost pressure accelerates the 7.18% CAGR for handheld devices priced at EUR 5,000-10,000 and influences the modality mix throughout the Italy ultrasound devices market.
Other drivers and restraints analyzed in the detailed report include:
For complete list of drivers and restraints, kindly check the Table Of Contents.
Critical-care ultrasound is projected to post a 5.83% CAGR, outpacing all other uses. The Italian ultrasound devices market for this segment benefits from 79% physician adoption of lung and cardiac protocols, serial hemodynamic monitoring, and bedside-guided procedures. Radiology still accounts for the largest slice at 38.13% of 2025 revenue, but its lower growth reflects competition from CT and MRI in complex cases. Parallel demand persists in cardiology, obstetrics-gynecology, musculoskeletal, and vascular clinics, each supported by specialty society guidelines that mandate ultrasound at defined intervals.
Radiology departments continue to purchase feature-rich consoles equipped with advanced Doppler and elastography, while ICUs and emergency rooms procure portable or handheld units optimized for infection-control and battery runtime. This bifurcation deepens channel specialization: purchasing teams increasingly split tenders by clinical domain to match device attributes with workflow needs. As a result, the Italy ultrasound devices market share for critical-care applications steadily rises within hospital budgets.
Three- and four-dimensional imaging captured 41.87% of 2025 technology revenue driven by obstetric and cardiac demand, yet high-intensity focused ultrasound (HIFU) is set to expand at a 5.33% CAGR. Oncology and orthopedics centers in Milan, Bologna, and L'Aquila now ablate bone metastases, osteoid osteoma, and uterine fibroids with MR-guided systems, supporting incremental procedure volumes. Broader SSN reimbursement could unlock applications for prostate and pancreatic cancers.
Doppler and conventional 2D remain essential for vascular mapping and abdominal exams, ensuring a diversified modality mix. Vendors court HIFU prospects by offering pay-per-treatment finance packages to offset capital outlays of EUR 1-2 million. Consequently, the Italy ultrasound devices market size for HIFU, while still small, exhibits outsized momentum relative to legacy modalities.